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Abstract
The 26S proteasome is a 2.4 MDa multifunctional ATP-
dependent proteolytic complex, which degrades the majority of
cellular polypeptides by an unusual enzyme mechanism. Several
groups of proteasome inhibitors have been developed and are now
widely used as research tools to study the role of the ubiquitin^
proteasome pathway in various cellular processes, and two
inhibitors are now in clinical trials for treatment of multiple
cancers and stroke. ß 2001 Elsevier Science Ltd. All rights re-
served.
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1. Introduction
The ubiquitin^proteasome pathway is the major proteo-
lytic system in the cytosol and nucleus of all eukaryotic
cells. This ATP-dependent pathway was discovered more
than 20 years ago [1,2], but the involvement of the pro-
teasome particle was demonstrated only in the late 1980s
[3]. Much of our initial understanding of the importance
of this pathway in the regulation of di¡erent cellular pro-
cesses came from biochemical studies in extracts of mam-
malian cells and genetic studies in yeast (reviewed in [4]).
However, knowledge about its physiological roles in mam-
malian cells was slow to develop until cell-permeable pro-
teasome inhibitors were developed, which greatly simpli-
¢ed such studies. Introduction of proteasome inhibitors
led to the demonstration that the proteasome catalyzes
the degradation not only of the majority of short-lived
but also of long-lived proteins, which comprise the bulk
of proteins in mammalian cells [5,6]. Studies using these
compounds have demonstrated that the ubiquitin^protea-
some pathway is responsible for the breakdown of a large
variety of cell proteins and is essential for many cellular
regulatory mechanisms (Table 1). For example, cell cycle
progression is controlled by the proteasomal degradation
of cyclins and inhibitors of cyclin-dependent kinases [7],
while degradation of transcriptional regulators, such as
c-Jun, E2F-1 and L-catenin (see [8] for review) is essential
for the regulation of cell growth and gene expression.
Similarly, degradation by the proteasome of activated pro-
tein kinases, e.g. src and protein kinase C [9,10], is critical
for the termination of certain signal transduction cascades.
The ubiquitin^proteasome pathway also plays an im-
portant role in the regulation of many physiological pro-
cesses as well as in the development of a number of major
human diseases. For example, degradation of the tumor
suppressor p53 (reviewed in [8]), and p27Kip1 inhibitor of
cyclin-dependent kinases [11] can promote tumorigenesis.
As discussed below, proteasomal degradation of the IUB
inhibitor of the transcription factor NF-UB is essential for
the development of in£ammatory response [12,13]. Fur-
thermore, the ubiquitin^proteasome pathway also plays
an essential role in immune surveillance [14], muscle atro-
phy [15], regulation of metabolic pathways [16^18], acqui-
sition of long-term memory [19], as well as in regulation of
circadian rhythms [20] and photomorphogenesis in plants
[21].
Another important function of the ubiquitin^protea-
some pathway is in the selective removal of mutant, dam-
aged and misfolded proteins. It has been claimed recently
that a large fraction (perhaps even one-third) of newly
synthesized proteins cannot fold properly and are de-
graded by the proteasome [22]. In addition, post-synthetic
damage, such as damage by oxygen radicals or isomeriza-
tion of aspartic acid residues, which occurs for example
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during in vitro ‘aging’ of calmodulin [23], can trigger rapid
degradation of a protein. Moreover, abnormal proteins,
which cannot fold because of mutation and are degraded
by proteasome (Table 1), are important causes of various
genetic diseases, including cystic ¢brosis [24,25] and he-
reditary K1-antitrypsin de¢ciency, a cause of emphysema
[26].
The majority of substrates of this pathway are marked
for degradation by covalent attachment of multiple mole-
cules of ubiquitin, a small 8 kDa protein (Fig. 1). First, the
ubiquitin is attached to a free amino group on the sub-
strate, generally through an isopeptide bond to the amino
group of a lysine side chain [8]. A chain of ubiquitins is
formed as several ubiquitin molecules are processively
added to the Lys-48 of the preceding ubiquitin. This
task is accomplished by three enzymes, E1, E2 and E3.
E1 activates the ubiquitin molecule in an ATP-dependent
process and transfers it to one of at least 15 di¡erent E2
ubiquitin carrier proteins. The ubiquitin is then transferred
to the substrate protein by an E3, an ubiquitin-protein
ligase. Eukaryotic cells contain perhaps hundreds of
E3 enzymes, and the speci¢city of the pathway is due
to the ability of di¡erent E3s to recognize di¡erent
degradation signals on the substrates. The resulting
ubiquitinylated proteins are then recognized and degraded
by a 2.4 MDa proteolytic complex, the 26S proteasome
[27].
Table 1
Physiological functions and selected substrates of ubiquitin^proteasome
pathway
Function Substrate
Cell cycle progression p27Kip1, p21, cyclins
Oncogenesis p53, p27Kip1, bax, IUB
Apoptosis Bcl-2, cIAP, XIAP
Regulation of gene ex-
pression
c-Jun, E2F1, IUB, L-catenin
In£ammation IUB, p105 precursor of NF-UB
Long-term memory Protein kinase A (regulatory subunit)
Regulation of metabolic
pathways
Ornithine decarboxylase, HMG-CoA
reductase
Immune surveillance Most cytosolic and nuclear proteins
Protein quality control CFTRvF508, K1-antitrypsin (Z-variant), aged
calmodulin
Regulation of circadian
clock
Timeless
Photomorphogenesis in
plants
Hy5
Fig. 1. The simpli¢ed scheme of the ubiquitin^proteasome pathway.
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2. 26S proteasome ^ a multifunctional proteolytic machine
The 26S proteasome is an ATP-dependent, multifunc-
tional proteolytic complex that di¡ers in many respects
from typical proteolytic enzymes (Table 2). It consists of
a proteolytic core particle, the 20S (720 kDa) proteasome,
sandwiched between two 19S (890 kDa) ‘cap’ regulatory
complexes [28], also termed PA700 (Fig. 2). These com-
plexes associate together in an ATP-dependent manner
[27,29]. Besides these 19S^20S^19S complexes, single-
capped 19S^20S complexes are likely to exist in vivo
[30,31], and it is unclear which of these forms is more
important in protein breakdown. In certain tissues and
cell types, single-capped complexes may also associate
with the interferon-Q (IFN-Q)-induced heptameric ring
PA28 (11S) complex [31], which is believed to stimulate
production of antigenic peptides by proteasomes [32] by
an unclear mechanism. In addition, free 20S proteasomes
as well as symmetric PA28^20S^PA28 complexes exist in
mammalian cells [30,31] but they are unable to degrade
ubiquitin-conjugated proteins and are not ATP-dependent.
Thus, they are unlikely to play a signi¢cant role in intra-
cellular proteolysis, which in vivo is an ATP-dependent
process [33].
The 20S proteasome is a hollow cylindrical particle con-
sisting of four stacked rings (Fig. 3). Each outer ring is
composed of seven di¡erent K subunits, while each inner
ring is composed of seven di¡erent L subunits [34]. Each L-
ring contains three di¡erent proteolytically active sites
(Fig. 3), which were identi¢ed by X-ray di¡raction as
the sites of binding of a peptide aldehyde inhibitor [35].
All these active sites face the inner chamber of the cylin-
der, and the only way for substrates to reach this chamber
is through the gated channels in the K-rings [35^37], which
is too narrow to be traversed by tightly folded globular
proteins [38]. Moreover, as demonstrated by X-ray di¡rac-
tion [35], these channels are completely closed in the free
latent 20S proteasomes. Thus, in contrast to the majority
of other proteases which have easily accessible active sites,
proteasomes have active sites which are con¢ned to the
inner cavity of the 20S core, thereby preventing uncon-
trolled destruction of the bulk of cellular proteins.
19S regulatory complexes control the access of sub-
strates into the proteolytic core (Fig. 2). Each 19S particle
consists of a base and a lid [27,39]. The lid, which contains
Table 2
Unique properties of 26S proteasome
b Enormous size (2.5 MDa), at least 44 polypeptides
b ATP-dependent
b Active sites segregated in secluded compartment
b Six proteolytically active sites with three di¡erent speci¢cities
b Degrades proteins processively
b N-terminal threonine-based proteolytic mechanism
b Can unfold globular proteins
b Substrate recognition by polyubiquitin chain
Fig. 2. The 26S proteasomes and its components. Electron tomography image [27] was kindly provided by W. Baumeister.
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at least nine polypeptides, is believed to bind to the poly-
ubiquitin chain with high a⁄nity and to cleave it away
from the substrate. The base, which associates with the
20S particle, consists of eight polypeptides including six
homologous ATPases of the AAA family. As demon-
strated by site-directed mutagenesis, these ATPases inter-
act directly with K-rings of the 20S core particle resulting
in the ATP-dependent opening of the channel in the K-
rings [40], which allows polypeptides access into the pro-
teolytic chamber of the 20S particle.
ATPases of the 19S complexes are also likely to unfold
the polypeptide and catalyze its translocation into 20S
proteasomes. In prokaryotes and archaea, which lack
ubiquitin but contain simpler 20S proteasomes [41], pro-
teasomes can be regulated by hexameric rings of ATPases
homologous to the ATPases of the 19S complexes [42,43].
These ATPases have been shown to mediate protein un-
folding [44] and facilitate entrance of substrates into the
core proteasome.
Unlike the great majority of proteases which cleave the
substrate once and then release the two fragments, protea-
somes degrade proteins in a processive fashion [45^47].
They cut polypeptides at multiple sites without the release
of polypeptide intermediates, generating peptides which
range from three to 22 residues in length with a median
size of six residues [46]. During this process the unde-
graded ubiquitin molecules are released by 19S particles
for reuse in degradation of other substrates.
3. Active sites of eukaryotic 20S proteasomes
Although the 26S proteasome exhibits many di¡erent
enzymatic activities, small molecule inhibitors are avail-
able only for the proteolytic sites of the 20S proteasomes.
Eukaryotic core particles contain six active sites, three on
each of its two central L-rings, and these proteolytic sites
di¡er in their speci¢cities (Fig. 3). Two termed ‘chymo-
trypsin-like’ cut preferably after hydrophobic residues
and have their catalytic residues located on the L5 sub-
units. Two sites, located on L2 subunits, are ‘trypsin-like’
in cleaving after basic amino acids. The two remaining
sites, located on L1 subunits, split peptide bonds preferen-
tially after acidic residues [47,48]. These latter sites were
traditionally termed ‘peptidyl glutamyl peptide hydrolase’
[49] ; however, it has been found that they cleave after
aspartic acid residues faster than after glutamates, and
therefore it was suggested that these sites be called ‘post-
acidic’ or ‘caspase-like’ [50]. (Caspases are intracellular
cysteine proteases, involved in cytokine processing and
apoptosis, which cleave proteins only after aspartates
[51].) It should be borne in mind that these names are
Fig. 3. The 20S proteasome. Schematic representation of the cross-section of the particle showing topology of the subunits and location of three active
sites. The entrance channel on the top of the particle is shown in the closed conformation, while the channel on the bottom of the particle is in the
open conformation. Location of the N-termini of K subunits, which are responsible for closing the channel, are shown according to the structure of
yeast proteasome with PA26 activator from Trypanosoma brucei, which is the structural homologue of the mammalian PA28 activator [152]. The
stippled areas represent the cut surfaces of the particle.
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imprecise and useful only to indicate their general similar-
ities to the substrate speci¢cities of ‘classical’ proteases,
though they do not imply any similarity in catalytic mech-
anisms or physiological functions.
It has been claimed, based on studies with model pep-
tides and inactivation by inhibitors, that mammalian pro-
teasomes also contain two other peptidase activities, re-
ferred to as ‘branched-chain amino acid-preferring’
(cleaving after leucines) and ‘small neutral amino acid-pre-
ferring’ [52]. However, the existence of additional active
sites responsible for these activities has been excluded by
X-ray di¡raction [35], extensive kinetic studies [53,54] and
site-directed mutagenesis [48]. Surprisingly, the cleavages
after branched-chain amino acids (i.e. leucine, isoleucine
and valine) are performed mainly by post-acidic (caspase-
like) sites [48,53,55], and to a lesser extent by the chymo-
trypsin-like sites [54]. Thus, the speci¢cities of the protea-
some’s active sites are actually broader than re£ected by
their names.
Substrate binding sites for each of these catalytic L sub-
units are formed as a result of speci¢c interactions of the
catalytic subunit with one of its adjacent L subunits
[35,36]. Consequently, subunits of the proteasome do not
exhibit proteolytic activity when expressed individually
and have not been detected in cells in the monomeric
form. Thus, the 20S proteasome is not a complex of di¡er-
ent individual proteases, but a unique multicatalytic en-
zyme whose multiple active sites function only as an inte-
gral part of this particle. Moreover, the activities of some
of these peptidase sites can be allosterically stimulated or
inhibited by peptide substrates acting on non-catalytic reg-
ulatory sites [50,56,57]. These ¢ndings thus suggest that
function of di¡erent active sites in protein breakdown is
a regulated or even an ordered process.
4. The proteasome’s unusual catalytic mechanism
Proteasomes, together with their bacterial homologue
HslVU complex [58], form a new class of proteolytic en-
zymes called threonine proteases. Unlike any other pro-
tease, all the proteolytic sites in proteasomes utilize N-
terminal threonines of L subunits as the active site nucle-
ophiles. The proteasome is a member of the growing
group of N-terminal nucleophile hydrolases, which have
similar 3D structure and utilize the side chains of their N-
terminal serine, threonine or cysteine residues to cleave
various amide bonds [59]. Much of our understanding of
this unique proteolytic mechanism has come through stud-
ies using inhibitors and site-directed mutagenesis [48,60].
Peptide aldehydes are well-characterized inhibitors of
two other classes of proteolytic enzymes, serine and cys-
teine proteases. They inhibit these enzymes reacting with
the catalytic hydroxyl or thiol groups in the active sites of
those enzymes to form a reversible hemi(thio)acetal, which
resembles a transition state analogue of the enzymatic re-
action [61]. Similarly, the peptide aldehyde Ac-Leu-Leu-
nLeu-al (commonly termed ALLN, Fig. 6) was shown by
X-ray di¡raction to form a hemiacetal bond with the hy-
droxyl group of the N-terminal threonines of the protea-
some’s L subunits (Fig. 7), strongly suggesting that this
hydroxyl is the catalytic nucleophile [35,36]. Accordingly,
mutation of this threonine to alanine completely abolished
the activity of the enzyme, while its mutation to serine
Fig. 4. Proteasome catalytic mechanism. Substrate is black, proteasome is cyan, and bonds formed during catalysis are blue.
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retained signi¢cant activity [60,62]. In addition, this threo-
nine residue is covalently modi¢ed by di¡erent inhibitors,
3,4-dichloroisocoumarin [45,63] (DCI, Fig. 6), lactacystin
[64], vinyl sulfones [65], and epoxyketones [12] (Figs. 5 and
7, see below).
The sensitivity of proteasomes to peptide aldehydes
strongly suggests that its hydrolytic mechanism resembles
the well-characterized mechanism of serine and cysteine
proteases, even though the proteasome lacks the classical
catalytic triad of these enzymes [36]. Instead, the free N-
terminal amino group of catalytic threonine is best posi-
tioned to accept the proton from the side chain hydroxyl,
which is transferred either directly or shuttled by a water
molecule [35]. The pKa of the N-terminal amino group
may be lowered by the side chain amino group of the
adjacent conserved Lys-33, which is essential for catalysis
[60,66,67].
The other features of the proteasome’s catalytic mecha-
nism must be similar to those of serine proteases. First, the
hydroxyl group of the proteasome’s catalytic threonine
directly attacks a scissile bond (Fig. 4). This attack results
in the formation of the tetrahedral intermediate, which
then collapses into an acyl enzyme with the release of
the ¢rst reaction product. Deacylation of catalytic threo-
nine residues by water leads to the formation of the second
product and the regeneration of free proteasomes.
Although an acyl enzyme intermediate has not been iso-
lated for the proteasome, the demonstration by X-ray dif-
fraction that the catalytic hydroxyl is acylated by the L-
lactone inhibitor (see below, Fig. 8) provides strong evi-
dence for its existence [35].
5. Major classes of proteasome inhibitors
Enzyme-speci¢c inhibitors of proteases are usually short
peptides linked to a pharmacophore, generally located at
its C-terminus. The pharmacophore interacts with a cata-
lytic residue with the formation of reversible or irreversible
covalent adduct, while the peptide portion speci¢cally as-
sociates with the enzyme’s substrate binding pocket in the
active site. Although the proteasome has multiple active
sites, inhibition of all of them is not required to signi¢-
cantly reduce protein breakdown. In fact, inhibition of the
chymotrypsin-like site or its inactivation by mutation
alone causes a large reduction in the rates of protein
breakdown [5,66,67]. In contrast, inactivation of trypsin-
like or caspase-like sites had little e¡ect on overall proteol-
ysis [46,67,68]. In addition, most inhibitors of chymotryp-
sin-like sites are highly hydrophobic and consequently
much more cell-permeable than inhibitors of the trypsin-
or caspase-like sites, which contain charged residues. Con-
sequently, almost all the synthetic and natural inhibitors
of the proteasome act predominantly on the chymotryp-
sin-like activity but also have some, usually much weaker,
e¡ects on the two other sites.Ta
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Although cleavages by the chymotrypsin-like sites ap-
pear to be rate-limiting in protein breakdown, the extent
of inhibition of chymotrypsin-like activity cannot be di-
rectly related to the reduction in protein breakdown be-
cause inhibition of this site may lead to the enhanced
cleavages by two other sites. Unfortunately, inhibitor po-
tency has often been measured only against the chymo-
trypsin-like activity with puri¢ed proteasomes and syn-
thetic peptide substrates. The various reports concerning
the potencies of di¡erent proteasome inhibitors in cells are
di⁄cult to compare because di¡erent investigators have
used diverse cell lines and assays, which were generally
only indirectly related to the rates of protein breakdown.
Thus, when comparing di¡erent inhibitors, in this review
we will use indicated degree of inhibition of chymotrypsin-
like activity, even though biological e⁄cacy should involve
capacity to inhibit degradation of whole proteins.
The chymotrypsin-like site of proteasomes cleaves pri-
marily after large hydrophobic residues, similar to the
preference of intracellular cysteine proteases such as cyto-
Fig. 5. Major proteasome inhibitors. Pharmacophores are red.
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solic calpains and many lysosomal cathepsins [69]. There-
fore, high selectivity of proteasome inhibition by peptide-
based compounds would be hard to achieve just by simply
manipulating the peptide portion of the inhibitor. Instead,
the use of a pharmacophore with preference for the pro-
teasome’s N-terminal threonine is required. Based on
pharmacophores, proteasome inhibitors can be divided
into several groups.
5.1. Peptide aldehydes
Peptide aldehydes were the ¢rst proteasome inhibitors
to be developed [5,70] and are still the most widely used
inhibitors. Aldehyde inhibitors of the chymotrypsin-like
site are slow-binding [70], but they enter cells rapidly
and are reversible. These inhibitors have fast dissociation
rates, are rapidly oxidized into inactive acids by cells and
are transported out of cell by the multi-drug resistance
(MDR) system carrier (J. Adams, personal communica-
tion). Consequently, in experiments involving cultured
mammalian cells and yeast, e¡ects of these inhibitors can
be rapidly reversed by removal of the inhibitor [71].
As discussed above, peptide aldehydes are well-known
inhibitors of cysteine and serine proteases, and thus can
inhibit such proteases in vivo. For example, ALLN, which
was used in earlier studies, was ¢rst described as a calpain
inhibitor I [72], and is 25-fold more potent against cathep-
sin B and calpain than the proteasome [5]. Many other
peptide aldehydes have been synthesized since [73,74],
but only a few of them are now used widely. MG132
(Z-Leu-Leu-Leu-al, also termed Cbz-LLL or z-LLL, Table
3 and Fig. 5) is not only signi¢cantly more potent than
ALLN against the proteasome [75], but is much more
selective, as shown by the fact that inhibition of calpains
and cathepsins requires at least 10-fold higher concentra-
tions [76]. Another peptide aldehyde, PSI (Z-Ile-Glu(Ot-
Bu)-Ala-Leu-al, Fig. 5), inhibits the proteasome 10-fold
better than calpain but is less potent than MG132 [77]
(Table 3). Finally, the dipeptide aldehyde CEP1612 (Fig.
5) appears at least as good as MG132 in potency and
selectivity [74] (Table 3), but is not available commercially.
Since MG132, PSI, MG115 (Z-Leu-Leu-nVal-al) and
ALLN can all inhibit calpains and various lysosomal cath-
epsins in addition to the proteasome, when using these
inhibitors in cell culture it is important to perform control
experiments to con¢rm that the observed e¡ects are due to
the inhibition of the proteasome. First, one can use agents,
which block intracellular cysteine proteases, but do not
inhibit proteasomes [5]. Such inhibitors are Z-Leu-Leu-
al, and E-64 for calpains [76], and weak bases such as
chloroquine and E-64 for lysosomal proteolysis [5]. In
yeast, where digestive vacuoles contain mainly serine,
not cysteine, proteases, phenylmethylsulfonyl £uoride can
be used to inhibit these enzymes without a¡ecting protea-
somes [71]. Moreover, with any e¡ect sensitive to MG132
or other aldehydes, involvement of the proteasome can be
con¢rmed [6] or ruled out [78] by use of several more
speci¢c inhibitors of the proteasome, such as lactacystin,
epoxomicin and boronate MG262 (Fig. 5 and Table 3, see
below), which would be too expensive for most investiga-
tors to use in routine studies.
Despite the availability of these inhibitors, MG132, due
to its low cost and the rapid reversibility of its action, still
remains, in our opinion, the ¢rst choice to study protea-
some involvement in a process in cell cultures or tissues, if
appropriate controls are used. As the most potent and
selective of commercially available aldehydes, MG132 is
preferable to ALLN, MG115 (Z-Leu-Leu-nVal-al), or
even PSI. On the other hand, the least selective inhibitor,
ALLN, because of its ability to inhibit most major pro-
Fig. 6. Non-selective inhibitors of proteasome. Pharmacophores are red.
CHBIOL 121 9-8-01 Cyaan Magenta Geel Zwart
746 Chemistry & Biology 8/8 (2001) 739^758
teases in mammalian cells, is probably the best tool for
prevention of unwanted proteolysis, for example during
isolation of proteins from mammalian cells.
5.2. Peptide boronates
Peptide boronates (Table 3 and Fig. 5) are much more
potent inhibitors of the proteasome than the aldehydes
[73]. The boronate analogue of MG132, MG262 (Z-Leu-
Leu-Leu-boronate), is 100-fold more potent than the alde-
hyde with an impressive Ki of 18 pM [73], and even some
dipeptide boronates have Ki values below 1 nM (Table 3).
The mechanism of inhibition by these slow-binding com-
pounds is yet to be con¢rmed by X-ray di¡raction, but it
is presumed that boronates, like peptide aldehydes, form a
tetrahedral adduct with the active site threonine (Fig. 7).
The boronate^proteasome adducts have much slower dis-
sociation rates than proteasome^aldehyde adducts, and
although boronates are considered reversible inhibitors,
the inhibition is practically irreversible over hours.
Boronates are also more selective inhibitors than alde-
hydes. Unlike aldehydes and vinyl sulfones (see below),
Fig. 7. Mechanisms of proteasome inhibition by di¡erent classes of peptide-derived inhibitors. Inhibitors are in black, except pharmacophores, which
are in red. Proteasome is in cyan, and newly formed bonds are blue.
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boronates are very poor inhibitors of thiol proteases, due
to the weak interactions between sulfur and boron [73].
Inhibition of serine proteases by many peptide boronates,
such as PS-341 (pyrazylcarbonyl-Phe-Leu-boronate, Fig.
5), is also 1000-fold weaker than that of the proteasome
[73]. An extensive search failed to identify any other tar-
gets of PS-341, aside from the proteasome, in the rat [79].
Boronates, unlike aldehydes, are not inactivated by oxida-
tion and are not rapidly secreted from cells by MDR
(J. Adams, personal communication).
This combination of potency, selectivity and metabolic
stability makes the peptide boronates (originally developed
at ProScript and now being developed by Millennium
Pharmaceuticals), better drug candidates than other
classes of proteasome inhibitors, and one of the dipeptide
boronates, PS-341, is currently in phase II clinical trials in
cancer patients (see below). Two other dipeptide boro-
nates, dansyl-Phe-Leu-boronate (DFLB, Fig. 5) and
PS-273 (morpholino-naphthylalanine-Leu-boronate, also
termed MNLB or MG273), are useful £uorescent probes
of the active sites, because binding of these inhibitors to
them enhances the £uorescence of the environment-sensi-
tive dansyl and naphthyl moieties [80].
5.3. Non-peptide inhibitors: lactacystin and L-lactone
Lactacystin is a Streptomyces metabolite, which was dis-
covered by Omura and coworkers as a result of its ability
to induce di¡erentiation of cultured neuronal cells [81] and
was later synthesized by Corey and coworkers [82]. In
studies of its mode of action, Fenteany et al. [64] found
that radiolabeled synthetic lactacystin selectively modi¢ed
the L5(X) subunit of mammalian proteasome and irre-
versibly blocked its activity. Other proteolytic sites of the
proteasome were also modi¢ed and reversibly inhibited
but at much slower rates [6,64]. Subsequent studies, how-
ever, demonstrated that lactacystin itself is not active
against proteasomes in vitro but, at neutral pH, undergoes
spontaneous transition to clasto-lactacystin-L-lactone [83]
(Figs. 5 and 8), for which the name ‘omuralide’ was sug-
gested [82]. Kinetic analysis demonstrated that this L-lac-
tone, but not lactacystin, reacts with the proteasome’s ac-
tive site threonines [83], resulting in the opening of the
L-lactone ring and acylation of the proteasome’s catalytic
hydroxyl (Fig. 8). The structure of the lactacystin^protea-
some complex was determined by X-ray di¡raction,
and provided strong evidence that an acyl enzyme conju-
gate is indeed an intermediate in catalysis by the protea-
some [35].
Plasma membranes of mammalian cells [84] and yeast
[71] are not permeable to lactacystin, but the L-lactone,
which is spontaneously formed in mammalian tissue cul-
ture media, easily enters cells [84] (Fig. 8). In yeast, lacta-
cystin is not active [71], probably because lactonization
does not occur in acidic media. The L-lactone is the least
stable of all proteasome inhibitors. It is rapidly hydrolyzed
by water at neutral pH and exists inside mammalian cells
in equilibrium with lactathione, an inactive product of its
reaction with glutathione [84]. In addition, although the
L-lactone is considered an irreversible inhibitor, its adduct
with proteasome is slowly (t1=2W20 h) hydrolyzed by
water, resulting in the recovery of proteolytic activity. Re-
placement of the catalytic threonine by serine in archaeal
proteasomes increases the rate of inactivation of proteo-
lytic activity and markedly increases the rate of hydrolysis
of this acyl enzyme [62], perhaps explaining why this L-lac-
tone does not inhibit most serine proteases. The only ser-
ine proteases known to be inhibited by the L-lactone are
cathepsin A, a lysosomal carboxypeptidase [85], and cyto-
solic tripeptidyl peptidase II [86]. Thus, the L-lactone is a
Fig. 8. Mechanism of proteasome inhibition by lactacystin and its L-lactone.
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signi¢cantly more selective proteasome inhibitor than pep-
tide aldehydes.
5.4. DCI
DCI, a broad irreversible inhibitor of serine proteases
[61] (Fig. 6), also inhibits proteasomes by covalent mod-
i¢cation of its N-terminal threonine [45,63]. The exact
mechanism remains unknown, but like L-lactone, DCI
contains a cyclical ester, suggesting that it inhibits the
proteasome by the formation of non-hydrolyzable acyl
enzyme. This compound is not useful for in vivo studies
due to its toxicity and lack of selectivity.
5.5. Peptide vinyl sulfones
Peptide vinyl sulfones are synthetic irreversible inhibi-
tors of proteasome ¢rst described by Bogyo et al. [65] that
covalently modify its catalytic L subunits (Table 3 and Fig.
5). The structure of the resulting covalent adduct is cur-
rently being determined by X-ray di¡raction (M. Groll,
personal communication). It seems most likely that the
hydroxyl group of the proteasome’s catalytic threonine
reacts with the double bond of the vinyl sulfone moiety
in a Michael addition (Fig. 7), since mutation of this
threonine to an alanine prevents modi¢cation of the L
subunit [65].
Peptide vinyl sulfones do not inhibit serine proteases,
but they were ¢rst described as inhibitors of cysteine pro-
teases [87], and therefore the selectivity of inhibition de-
pends on the peptide portion of the inhibitor. For exam-
ple, replacement of the benzyloxycarbonyl (Z) group in
ZLVS (Z-Leu3-VS), a vinyl sulfone analogue of MG132,
by the 3-nitro-4-hydroxy-5-iodophenylacetate (NIP) group
to generate NLVS (Fig. 5) signi¢cantly reduced the inhi-
bition of cathepsins B and S [65].
Vinyl sulfones are easier to synthesize than other irre-
versible inhibitors of the proteasome, and an advantage of
such covalent inhibitors is that they can be used as sensi-
tive active site probes [65] for mechanistic studies of pro-
teasomes in di¡erent tissues and cells. Several vinyl sul-
fones containing tyrosine or a nitrophenyl group were
synthesized to allow easy radioiodination. Incubation of
cellular extracts with such compounds results in the cova-
lent attachment of the radiolabeled compounds to the ac-
tive subunits of the proteasome, which can then be iden-
ti¢ed by comparing the mobility of radioactive spots on
2D gels with the known pattern of proteasomal subunits
on 2D gels. Two compounds most widely used as probes
are NLVS, which modi¢es predominantly the chymotryp-
sin-like subunits, and [125I]YL3VS (Tyr-Leu-Leu-Leu-VS),
which reacts with all subunits, although at di¡erent rates
[88,89]. Most recently, the compounds NIP-Leu-Leu-Asn-
VS [90] and Ada-[125I]Tyr-Ahx3-Leu3-VS, which react with
all three active sites at comparable rates, and a biotinyl-
ated analogue of one of them, Ada-Lys(Bio)-Ahx3-Leu3-
VS, have been synthesized [91].
5.6. Epoxyketones
A major recent development was the discovery that nat-
ural epoxyketones (KP,LP-ketoepoxides), such as epoxomi-
cin and eponemycin (Fig. 5), isolated based on their anti-
tumor activity in mice, exert their biological e¡ects by
proteasome inhibition [12,92]. Epoxomicin reacts primar-
ily with the chymotrypsin-like site, while the less potent
epoxyketone eponemycin and its synthetic analogue dihy-
droeponemycin (Fig. 5) react with the caspase-like and
chymotrypsin-like sites at similar rates (Table 3). These
compounds act by an interesting and unique mechanism,
in which they react with both the hydroxyl and amino
groups of the catalytic N-terminal threonine of the pro-
teasome (Fig. 7). The crystal structure of the yeast protea-
some in complex with epoxomicin revealed a six-mem-
bered morpholine ring, formed by the N-terminal
threonine and epoxyketone moiety of the inhibitor [93].
This structure suggests that the catalytic hydroxyl ¢rst
attacks the carbonyl group of the pharmacophore (Fig.
7). Then, the free K-amino group of the threonine opens
up the epoxy ring and completes the formation of the
morpholino adduct [93]. Biotinylated derivatives of epox-
omicin and eponemycin were also prepared and these in-
hibitors, like vinyl sulfones, can be used as active site
probes.
Epoxyketones, because of their unique mechanism, are
the most selective inhibitors of the proteasome known.
Indeed, proteasomal subunits are the only cellular proteins
covalently modi¢ed by the biotinylated derivatives of ep-
oxomicin and eponemycin [12,92]. In addition, epoxomi-
cin, in contrast to the homologous aldehyde, did not in-
hibit any other proteolytic enzyme tested [12]. However,
the possibility that these epoxyketones may reversibly in-
hibit other enzymes has not been studied.
The reason for this high speci¢city of epoxyketones
most likely lies in their ability, in 2(R) con¢guration, to
take speci¢c advantage of the proteasome’s unique cata-
lytic mechanism by forming a cyclical morpholino ring
(Fig. 7). Epoxyketones cannot form such a ring with a
cysteine or a serine protease, because these enzymes do
not have a free N-terminus adjacent to the nucleophilic
group [93]. Although some epoxides, for example E-64,
inhibit cysteine proteases, they have a second electrophilic
carbonyl group adjacent to the pharmacophore and
(S) con¢guration at the C2 atom of the epoxy ring, while
in the proteasome inhibitors this atom has the (R)
con¢guration [93]. Inverting the con¢guration from R
to S dramatically decreased the potency of proteasome
inhibition [12], probably because the formation of the
morpholine ring was sterically hindered in 2(S) epimers
[93].
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5.7. Other classes of synthetic proteasome inhibitors
Other classes of synthetic proteasome inhibitors have
been reported. These include reversible peptide K-ketoal-
dehydes [94] and K-ketoamides [95], which are similar to
aldehydes in potency and selectivity, and indanone pep-
tides [96], which are even less potent. Thus, these com-
pounds do not appear to o¡er any advantage over other
classes of inhibitors.
5.8. Bivalent inhibitors
Bivalent inhibitors of the proteasome were generated by
tethering two peptide aldehydes with a £exible polyethyl-
eneglycol (PEG) linker, long enough to span the distance
between two active sites [97]. Although the resulting inhib-
itors were 100-fold more potent that their monovalent
analogues, it is very unlikely that these PEG-tethered com-
pounds will be cell-permeable. However, these agents or
analogous bivalent inhibitors with di¡erent pharmaco-
phores may be useful tools for certain studies on the pu-
ri¢ed particles.
5.9. New natural compound inhibitors
Recently several agents capable of inhibiting the protea-
some have been found among natural compounds (Fig. 9).
TMC-95A, a cyclic peptide metabolite of Apiospora mon-
tagnei, is a potent competitive inhibitor of the chymotryp-
sin-like activity of pure 20S proteasomes (Ki = 2.3 nM),
but also inhibits caspase-like and trypsin-like activities
[98]. In contrast to other inhibitors, whose mode of inhi-
bition was studied by X-ray di¡raction, TMC-95A does
not modify catalytic threonine but binds to the active site
by an array of hydrogen bonds between inhibitor and
enzyme active sites [99]. At low micromolar concentra-
tions, this compound showed cytotoxicity against cancer
cell lines, but it is not yet clear whether this toxicity is due
to the inhibition of protein breakdown.
Gliotoxin (Fig. 9) is fungal metabolite, which inhibits
proteasomes by an unusual mechanism [100]. In vitro
this non-peptide cyclic compound allosterically inhibits
the chymotrypsin-like activity of 20S proteasome by bind-
ing to an unknown non-catalytic site, whereas all other
inhibitors bind at the proteolytic sites. The disul¢de bridge
in gliotoxin is essential for its activity, suggesting that it
acts by forming mixed disul¢de bond with a proteasomal
subunit. In cell culture, gliotoxin completely blocks degra-
dation of IUB and other proteasome substrates, but at
almost 100-fold lower concentrations than required for
similar inhibition of puri¢ed proteasomes. Therefore, it
remains to be proved whether proteolytic activities of
the 20S proteasome are indeed the main targets of this
inhibitor in vivo.
Green tea contains many cathechin-3-gallate derivatives.
Several of these polyphenol compounds, especially (3)-
epigallocatechin-3-gallate (EGCG) (Fig. 9), were found
to be potent inhibitors of proteasome peptidase activities
[101]. EGCG also inhibited degradation of several sub-
strates of the pathway in cell culture and arrested cells
in G1 phase of the cell cycle. Structure^activity relation-
ship studies, atomic orbital energy analysis and analysis of
the products of EGCG interaction with proteasome
strongly suggested that the ester bond in this molecule is
attacked by the proteasome leading to the acylation of the
reactive site threonine. The mechanism of proteasome in-
hibition by EGCG thus resembles that of lactacystin-L-
lactone. Analysis of the reaction products suggests also
that, like the proteasome-L-lactone adduct, proteasome-
gallic acid acyl enzyme adduct is slowly hydrolyzed by
water, leading to the reactivation of the proteasome.
5.10. Proteasome as the secondary target of di¡erent drugs
Finally, the chymotrypsin-like activity of the protea-
some can also be inhibited by several major drugs, which
were all developed as inhibitors of other enzymes. These
include ritonavir, an inhibitor of the HIV-encoded aspartic
protease [102], the lactonized pro-drug form of the HMG-
CoA reductase inhibitor lovastatin [103], the anti-cancer
DNA-intercalating agent aclacinomicin A (aclarubicin)
[104], and the immunosuppressive agent cyclosporin A
[105]. Although it is not clear whether these drugs have
any e¡ect on protein breakdown in vivo at their therapeu-
Fig. 9. New natural product inhibitors of the proteasome.
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tic concentrations, these examples emphasize that any
statement about the speci¢city of small molecules, based
solely on in vitro studies, may not hold true in vivo.
6. Biological e¡ects of proteasome inhibitors
Inhibitors of the proteasome have been essential tools in
the discovery of many new substrates of the ubiquitin^
proteasome pathway and establishing its role in di¡erent
biological processes. Because of the importance of protea-
some in many aspects of cellular function, its inhibitors
have multiple, profound and often complex e¡ects on liv-
ing cells.
6.1. Inhibition of protein breakdown and its measurement in
cells
The primary, immediate consequence of proteasome in-
hibition is a decrease of overall rates of protein breakdown
in cells [5,6]. The concentrations of inhibitors required to
cause such e¡ects vary with the cell line [6]. The measure-
ment of inhibitor e⁄cacy in cells or extracts can be a
major experimental challenge, and a number of the ap-
proaches used to measure e⁄cacy of inhibitors in vivo
are, at best, qualitative guides to inhibitor potency. As
noted above, the degree of inhibition of the chymotryp-
sin-like activity is a useful qualitative measure of e⁄cacy
against proteins, but it does not indicate the actual reduc-
tion in degradation of proteins, especially if the inhibitor
also a¡ects the activity of the proteasome’s other sites. By
labeling cell proteins with radioactive amino acids, and
then following the overall rates of breakdown of the radio-
labeled species, it is possible to directly measure the total
rate of intracellular proteolysis [33]. This approach has
been used to measure the actual in vivo inhibition of pro-
tein breakdown by certain peptide aldehydes and lactacys-
tin [5,6,71]). However, for many commonly used inhibitors
(e.g. epoxomicin or vinyl sulfones), the capacity to reduce
the overall rate of protein degradation in cells has still
never been reported. The decay curves of radiolabeled
cell proteins are complex exponential functions that ini-
tially re£ect the hydrolysis of many short-lived proteins
(half-life shorter than 2 h). With time, these curves re£ect
presumably the breakdown of long-lived proteins, whose
half-lives range from hours to days. It is also possible in
principle to follow the exponential breakdown of individ-
ual proteins (usually by immunoprecipitation) after either
radiolabeling or blocking protein synthesis.
Several groups have attempted to quantitate inhibitor
e⁄cacy by measuring the accumulation of short-lived pro-
teins. However, it should be noted that this approach does
not re£ect the degree of inhibition of proteolysis, since the
buildup of a protein is determined both by its rate of
synthesis and by its degradation rate. Also, since degrada-
tion is an exponential process, the actual e¡ects on protein
levels also depend on the protein’s initial content and the
number of half-lives over which this process is measured.
Finally, in any period (e.g. several hours) an inhibitor
would be expected to have a much larger e¡ect on the
levels of a short-lived protein than on a long-lived cell
protein. For example, in the absence of synthesis, a 50%
inhibition of proteolysis should double in 1 h the level of a
protein with a half-life of 1 h, but should have a negligible
e¡ect on the levels of a protein with a half-life of 1 day
(the average half-life of proteins in cell culture).
6.2. Induction of heat shock response
A decrease of overall rates of protein breakdown in cells
[5,6] leads to rapid accumulation of short-lived proteins
conjugated to ubiquitin [22,77,106]. Proteasome inhibition
also causes an accumulation of misfolded and damaged
proteins, which may constitute a large fraction (up to
one-third) of newly synthesized polypeptides [22]. This ac-
cumulation of unfolded polypeptides triggers expression of
heat shock proteins, stress proteins of the endoplasmic
reticulum and, in yeast, accumulation of the thermopro-
tective disaccharide trehalose [107,108]. Consequently,
even a short exposure (30^60 min) of cells to proteasome
inhibitors protects them against various kinds of toxic
conditions, such as increased temperature or oxygen rad-
icals [108]. Transcriptional pro¢ling with DNA microarray
analysis of human cancer cells exposed to proteasome in-
hibitor con¢rmed the induction of heat shock genes, genes
encoding proteasome subunits, as well as enzymes of ami-
no acid and polysaccharide metabolism and a number of
unknown genes [109]. Thus, inhibition of proteasome leads
to a large number of changes in the cell.
6.3. Cytotoxicity of proteasome inhibitors
Although short-term exposure to proteasome inhibitors
protects cells from a variety of toxic stimuli, long-term
exposure to these compounds is toxic to nearly all cells
and causes death by apoptosis. However, the relation be-
tween the degree and the duration of the reduction in
proteolysis and apoptosis is unclear as the concentration
of inhibitors [110,111] and length of exposure leading to
cell death varies between cell types. Several studies dem-
onstrated that proliferating cell lines are usually more sen-
sitive to proteasome inhibitors than non-proliferating ones
[112^116], and may undergo apoptosis within 4^48 h after
addition of the inhibitor [112,117^119].
This greater sensitivity of proliferating cells to apoptosis
may be a consequence of cell cycle arrest caused by the
inhibition of the proteasome [79,111,120^122], as the pro-
teasome is essential for the progression through many
steps in the cell cycle [7]. Another possible reason for
the higher toxicity of proteasome inhibitors in proliferat-
ing cells could be that these cells are more e⁄cient in
uptake, or slower in inactivating these compounds. Induc-
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tion of apoptosis by proteasome inhibitors in certain cells
has been attributed to the stabilization of the tumor sup-
pressor protein p53 [117,121], a short-lived protein de-
graded by the proteasomes, whose accumulation can trig-
ger the cell death program. However, proteasome
inhibitors can also cause apoptosis in cell lines lacking
p53 [79,110]. In addition, many other critical regulatory
proteins, for example the cdk inhibitor p27 [11] or the
proapoptotic protein bax [123], are stabilized, and various
abnormal proteins accumulate when proteasome is inhib-
ited. In fact, the build-up of such unfolded proteins alone
can activate the stress kinase c-Jun N-terminal kinase
(JNK), which can turn on the apoptotic cascade [118].
Inhibition of proteasome also prevents activation of NF-
UB, which is a potent inhibitor of apoptosis [124]. Thus,
toxicity of proteasome inhibitors is probably due to multi-
ple factors, including simply the changes in normal protein
composition of the cell, which must disturb homeostasis.
Recently, the cytotoxicity of several di¡erent inhibitors
has been compared in EL4 cells in culture. Princiotta et al.
[125] found that PS-341 is the most potent inhibitor, fol-
lowed closely by epoxomicin and MG262. MG132 was 10-
fold less potent that its boronate analogue (MG262). Lac-
tacystin had to be present in 10-fold higher concentrations
than MG132 to achieve the same e¡ect, and NLVS was
half as potent as lactacystin (Table 3).
In striking contrast to the e¡ects on proliferating cells,
less than 16 h treatment by proteasome inhibitors makes
non-proliferating thymocytes and neuronal cell lines more
resistant to apoptosis induced by ionizing radiation, glu-
cocorticoids, phorbol ester, etoposide or deprivation of
nerve growth factor [126^128]. Apoptosis may be tempo-
rarily inhibited because of the stabilization of the inhibi-
tors of apoptosis bcl-2 and IAPs, which are degraded by
the proteasome in response to certain apoptotic stimuli
[129,130]. However, longer exposures of thymocytes to
inhibitors eventually lead to death by apoptosis.
6.4. Anti-tumor e¡ects of proteasome inhibitors
The ability of proteasome inhibitors to inhibit cell pro-
liferation and selectively induce apoptosis in proliferating
cells, together with their ability to inhibit angiogenesis
[113,131], makes these agents attractive candidates as
anti-cancer drugs. In addition, certain cancer cells require
growth factors such as interleukin (IL) 4 and IL-6, whose
production depends on NF-UB, and NF-UB activation is
blocked by proteasome inhibitors [75]. Indeed, the boro-
nate inhibitor PS-341 (developed originally by ProScript
and now in clinical development by Millennium Pharma-
ceuticals), after showing impressive anti-proliferative ef-
fects in several animal model systems and cell culture
[79,132,133], is currently in NCI-sponsored human clinical
trials for the treatment of many di¡erent forms of cancer
[134]. The results of phase I trials showed surprisingly low
toxicity and no bone marrow suppression at concentra-
tions that appear to cause signi¢cant inhibition of the
proteasome (J. Adams, Millennium Pharmaceuticals, per-
sonal communication).
6.5. Adaptation and resistance to proteasome inhibitors
Although prolonged exposure to proteasome inhibitors
is toxic to almost all cells, in one cell line (EL-4), a small
fraction of cells (0.3%) exposed to the proteasome inhib-
itors NLVS and L-lactone were able to escape death and
to multiply after a period of adaptation [86,135]. It was
originally concluded that proteasome function was com-
pletely lost in these adapted cells, and that an alternative
pathway for proteolysis existed [135]. However, subse-
quent analysis demonstrated that, while chymotrypsin-
like activity is indeed completely inhibited, two other ac-
tive sites retain some activity [89]. The exact mechanism of
adaptation is unclear, but tripeptidyl peptidase II (TPPII),
a very large cytosolic oligopeptidase, is induced in adapted
cells, and overexpression of this peptidase has been found
to increase the cells’ resistance to NLVS [86,89]. Presum-
ably, increased levels of TPPII and possibly other pepti-
dases can compensate for the impaired proteasomal activ-
ity, which would be insu⁄cient for survival under normal
circumstances, perhaps by helping the cell to remove par-
tially digested fragments.
It has recently been reported that Burkitt’s lymphoma
cell lines are resistant to apoptosis induced by proteasome
inhibitors [136]. Although proteasomal peptidase activities
were signi¢cantly reduced in these cells, the overall rates of
protein breakdown were not changed. As in NLVS-
adapted cells, in Burkitt lymphoma cells it was found
that the activity and content of TPPII are increased, and
this e¡ect appears to be due to the constitutively activated
c-myc oncogene. Moreover, the inhibitor of TPPII Ala-
Ala-Phe-chloromethylketone (AAF-cmk), in contrast to
proteasome inhibitors, was able to inhibit proliferation
of these cells, suggesting that upregulation of TPPII
can indeed compensate for the decreased overall activity
of proteasome in these cancer cell lines. However, this
chloromethylketone also inhibits aminopeptidases [137]
and may alkylate cellular proteins.
6.6. Anti-in£ammatory activity of proteasome inhibitors
The critical biochemical event in the initiation of the
in£ammatory response is the rapid destruction of the in-
hibitory protein IUB which occurs in response to various
toxic stimuli. IUB was the ¢rst substrate of the ubiquitin^
proteasome pathway identi¢ed with the help of protea-
some inhibitors [75]. IUB is an inhibitor of transcription
factor NF-UB, which activates the expression of many
genes encoding in£ammatory mediators (e.g. tumor ne-
crosis factor, IL-1), enzymes (cyclooxygenase, nitric oxide
synthetase) and leukocyte adhesion molecules (ICAM,
VCAM) [138]. Consequently, in cultured cells and in
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vivo, proteasome inhibitors, by stabilizing IUB, maintain
NF-UB in the inhibited state and prevent production of
these proteins. In animal models the proteasome inhibitors
PS-341 and epoxomicin (Fig. 5) exhibit potent e¡ects
against arthritis and other in£ammatory conditions
[12,13,139]. The potent analogue of lactacystin-L-lactone
PS-519 (Fig. 5) [140] has anti-in£ammatory e¡ects in ani-
mal models of asthma [141]. Moreover, this compound
was shown to reduce reperfusion injury in the brain
[142] and improve neurological recovery after ischemic in-
jury [143], and it is currently in phase I clinical trials for
the treatment of stroke. On the other hand, proteasome
inhibition stabilizes short-lived cyclooxygenase II, a crit-
ical enzyme involved in synthesis of in£ammatory prosta-
glandins in the neuronal cell line, which by itself can be
potentially pro-in£ammatory [119].
6.7. Anti-HIV e¡ects of proteasome inhibitors
Recently several groups of investigators demonstrated
that proteasome inhibitors block release and maturation
of HIV and other retroviruses (reviewed in [144]). The
e¡ect appears to be indirect, due to the depletion of
pool of free ubiquitin, whose conjugation to viral Gag
polyproteins is required for virus release from the cell
but does not target Gag proteins for proteasomal degra-
dation. Nevertheless, it has even been suggested that pro-
teasome inhibitors can be used for the treatment of HIV
infection [145].
6.8. Inhibition of antigen presentation
The proteasome also plays a key role in immune sur-
veillance against viruses and cancer [14]. Protein degrada-
tion within the cells is the source of the 8^10 residue anti-
genic peptides presented to the cytotoxic T-lymphocytes
on the surface of the cells in association with major his-
tocompatibility (MHC) class I molecules. The ¢rst in vivo
study of proteasome inhibitors demonstrated that blocking
the proteasome reduces the generation of peptides used in
MHC class I antigen presentation [5]. Apparently, a frac-
tion of peptides generated during continuous degradation
of cell proteins escape complete destruction to amino
acids, are taken up by the endoplasmic reticulum and
then transported to the cell surface bound to MHC mol-
ecules. Subsequent studies demonstrated that proteasome
is absolutely essential for the generation of the C-terminus
of the MHC class I ligands, while their N-termini can be
generated as a result of trimming of proteasomal products
by cytosolic aminopeptidases (reviewed in [14]).
Interestingly, while presentation of the majority of epi-
topes is reduced by proteasome inhibitors, presentation of
a few others was stimulated by low concentrations of these
compounds, leading some investigators to conclude that
other proteinases may be involved in the generation of
these epitopes (reviewed in [14]). However, at higher con-
centrations, which block all proteasome function, pre-
sentation of these antigens is inhibited, and the alternative
explanation of these data would be that the chymotrypsin-
like site, the primary target of inhibitors used in those
experiments, both generates and destroys these epitopes
[146]. Now that cell-permeable and site-selective inhibitors
of caspase-like sites are available (see below) and when
such compounds become available for the trypsin-like
site, it should be possible to determine whether these
two sites also generate or destroy epitopes in a similar
fashion. Indeed, recent in vitro experiments with puri¢ed
26S proteasomes demonstrated that epitope is generated
only a small fraction of the time that a protein is de-
graded, and, most often, proteasomes cut within the epi-
tope [147].
This role of the proteasome in both defending against
viruses and cancer is also regulated by cytokines, espe-
cially by the immune activator IFN-Q. In fact, exposure
of cells to IFN-Q causes the induction of three alternative
catalytic subunits, LMP2 (L1i), LMP7 (L5i) and MECL1
(L2i), which enhance the production of MHC class I li-
gands or their precursors [14].
7. Subunit-speci¢c inhibitors
As discussed above, speci¢c inhibitors of individual ac-
tive sites could be valuable tools to study antigen presenta-
tion. As all the active sites cleave peptide bonds by the
same catalytic mechanism, subunit speci¢city of the inhib-
itors cannot be achieved by using di¡erent pharmaco-
phores, and one needs to de¢ne in detail di¡erences in
the substrate binding pockets of three active sites. The
majority of proteasome inhibitors currently available pri-
marily inhibit the chymotrypsin-like activity, but none of
them are highly speci¢c, because they also partially block
at least one of the remaining two activities (Table 3).
However, systematic replacement of residues in the pep-
tide portion of epoxomicin led to the generation of much
more selective Ac-hPhe-Leu-Phe-Leu-EX (YU101), which
was not only four-fold more potent against chymotrypsin-
like activity [148], but inactivated two other activities at 8^
24 000-fold slower rates (Table 3).
The speci¢c inhibitor of trypsin-like activity, the peptide
aldehyde maleinimido-LAla-Val-Arg-al, is a good example
of structure-based design [149]. The maleinimide moiety of
this inhibitor reacts covalently with the free thiol group of
the cysteine residue in the S3 binding pocket of the tryp-
sin-like site, resulting in its selective and irreversible inhi-
bition. However, this compound is very likely to be inac-
tivated within cells as a result of the reaction of
maleinimide with glutathione, limiting the application of
this inhibitor only to cell-free systems.
Recently, Nazif and Bogyo [90] made the interesting
observation that several peptide vinyl sulfones with an
asparagine residue in the P1 position reacted with L2 sub-
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units, responsible for the trypsin-like activity, faster than
with other subunits. Using positional scanning combina-
torial libraries, these authors generated potent and highly
selective inhibitors of the trypsin-like activity, Ac-Pro-Arg-
Leu-Asn-VS and Ac-Tyr-Arg-Leu-Asn-VS. Unfortunately,
these compounds appear not to enter cells readily (M.
Bogyo, personal communication).
AEBSF (Pefablock) is another compound that irre-
versibly inactivates the trypsin-like site without a¡ecting
two others [54]. This general inhibitor of serine proteinases
has been used in vitro to study the role of the trypsin-like
site in protein breakdown by puri¢ed proteasomes [46].
Speci¢c inhibitors of the caspase-like site were also gen-
erated recently. A cell-permeable epoxyketone, Ac-Gly-
Pro-Phe-Leu-EX (YU102), inactivates the caspase-like ac-
tivity 50-fold faster than chymotrypsin-like activity [57].
The peptide aldehyde Ac-Ala-Pro-Nle-Asp-al is even
more selective, and has a Ki for the caspase-like activity
below 1 WM, but its cell permeability has not been tested
yet (A. Kisselev et al., in preparation). The physiological
consequences of inhibition of this site are unclear.
8. Conclusions
The last few years have witnessed major progress in our
understanding of intracellular protein degradation. These
advances have in part been made possible by the discovery
of synthetic and naturally occurring inhibitors of protea-
somal proteolytic activities. We expect that subunit-specif-
ic, cell-permeable inhibitors will be added to this palette
of reagents in coming years. Of particular interest will
be the generation of inhibitors of non-proteolytic compo-
nents of the 26S proteasome and of the ubiquitin conju-
gation enzymes. Recent developments in combinatorial
chemistry and high-throughput screening and structure-
based design, as well as new assays of in vivo protein
breakdown [150,151], should speed up identi¢cation of
such molecules and may also lead to the new non-peptide
inhibitors of the proteasome. Use of genomics and proteo-
mics approaches will allow the analysis of the e¡ects of
these inhibitors on global patterns of gene expression and
protein composition of the cell, paving the way to a much
better understanding of the biological roles of the protea-
some.
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